Skip to content
Search

Latest Stories

Vedanta seeks to raise $1 billion for debt repayment

The conglomerate is also negotiating with its bondholders for modifications of repayment deadlines

VEDANTA RESOURCES is holding talks with private equity firms to raise funds for partial repayment of the company’s bonds maturing in the next two years, according to media reports.

The London-based conglomerate, led by billionaire tycoon Anil Agarwal, is in advanced discussions with Cerberus Capital, Ares SSG Capital, Bain Capital and Davidson Kempner, seeking a short-term loan of $1 billion, the Economics Times reported.

The repayment of its bonds worth $1 bn is due in January next year, followed by bonds worth another $1 bn maturing in August 2024. The company also has an obligation to repay bonds of $1.2 billion maturing in March 2025.

Vedanta is also negotiating with its bondholders for modifications of the repayment deadlines.

It has proposed to prepay 30 per cent of the bonds upfront and rolling over the rest over three years, the report said.

The company told its bondholders that it was looking to divest some of its steel and mining assets to raise funds, an effort which would take more than a year.

Its fundraising efforts come as S&P Global Ratings has warned of a possible downgrade of the company’s offshore bonds if the bondholders are not adequately compensated.

A Vedanta spokesperson told the Economic Times that the company “is in continuous discussions with its bondholders in the ordinary course including to address upcoming maturities.”

Vedanta “is in discussion with numerous parties in both the bank and fund community in addition to existing bond holders as it explores various options," the spokesperson said.

Separately, Vedanta’s subsidiary Vedanta Ltd said on Thursday (21) that its board approved a decision to raise up to $300 million through non-convertible debentures.

Vedanta Ltd shares hit their 52-week low on Thursday and closed with a 2.26 per cent decline on the BSE.

More For You

modi-trump-getty
Trump shakes hands with Modi during a joint press conference at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)

Key issues in India, US trade talks

TRADE talks between India and the US have hit a roadblock over disagreements on duties for auto components, steel and farm goods, Indian government sources said to Reuters, dashing hopes of reaching an interim deal ahead of president Donald Trump's July 9 deadline to impose reciprocal tariffs.

Here are the key issues at play:

Keep ReadingShow less
Trump-Getty

Trump said that while deals are being made with some countries, others may face tariffs.

Getty Images

Trump says major trade deal with India may be finalised soon

US PRESIDENT Donald Trump on Friday said a "very big" trade deal could be finalised with India, suggesting significant movement in the ongoing negotiations between the two countries.

“We are having some great deals. We have one coming up, maybe with India. Very big one. Where we're going to open up India," Trump said at the “Big Beautiful Bill” event at the White House.

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
Mounjaro

Mounjaro, or tirzepatide, is part of a new class of weight-loss medications, with trials showing patients losing an average of 20 per cent of their body weight after 72 weeks.

Reuters

Lilly to sell Mounjaro pens in India as Wegovy enters market

ELI LILLY said on Thursday that it has received approval from India's drug regulator to launch pre-filled injector pens of its weight-loss drug, Mounjaro.

The move gives the company more options to compete with Novo Nordisk, which recently launched its weight-loss drug Wegovy in the country.

Keep ReadingShow less
Grant Thornton's Anuj Chande urges UK firms to tap booming India

Anuj Chande

Grant Thornton's Anuj Chande urges UK firms to tap booming India

INDIAN companies are well placed to support the UK’s economic growth, Eastern Eye has been told by Anuj Chande, partner and head of the South Asia Business Group at Grant Thornton.

He was speaking after the publication of Grant Thornton’s India Meets Britain Tracker 2025: The latest trends in Indian investment in the UK, which was released last week. While companies in India need little encouragement to enter the UK market, the reverse is not true.

Keep ReadingShow less